Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP528004.RAvgqDt1S0qHs9AHMR_tBbeJFIloxFR9QUMS4zkFEPTao130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP528004.RAvgqDt1S0qHs9AHMR_tBbeJFIloxFR9QUMS4zkFEPTao130_assertion type Assertion NP528004.RAvgqDt1S0qHs9AHMR_tBbeJFIloxFR9QUMS4zkFEPTao130_head.
- NP528004.RAvgqDt1S0qHs9AHMR_tBbeJFIloxFR9QUMS4zkFEPTao130_assertion description "[Although cetuximab, an anti-EGF receptor (EGFR) monoclonal antibody, is an effective treatment for patients with KRAS wild-type metastatic colorectal cancer (mCRC), its clinical use is limited by onset of resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP528004.RAvgqDt1S0qHs9AHMR_tBbeJFIloxFR9QUMS4zkFEPTao130_provenance.
- NP528004.RAvgqDt1S0qHs9AHMR_tBbeJFIloxFR9QUMS4zkFEPTao130_assertion evidence source_evidence_literature NP528004.RAvgqDt1S0qHs9AHMR_tBbeJFIloxFR9QUMS4zkFEPTao130_provenance.
- NP528004.RAvgqDt1S0qHs9AHMR_tBbeJFIloxFR9QUMS4zkFEPTao130_assertion SIO_000772 24122793 NP528004.RAvgqDt1S0qHs9AHMR_tBbeJFIloxFR9QUMS4zkFEPTao130_provenance.
- NP528004.RAvgqDt1S0qHs9AHMR_tBbeJFIloxFR9QUMS4zkFEPTao130_assertion wasDerivedFrom befree-20150227 NP528004.RAvgqDt1S0qHs9AHMR_tBbeJFIloxFR9QUMS4zkFEPTao130_provenance.
- NP528004.RAvgqDt1S0qHs9AHMR_tBbeJFIloxFR9QUMS4zkFEPTao130_assertion wasGeneratedBy ECO_0000203 NP528004.RAvgqDt1S0qHs9AHMR_tBbeJFIloxFR9QUMS4zkFEPTao130_provenance.